0GFH Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improved Balance-sheet ResilienceLower leverage and roughly 97M of equity provide a stronger financial cushion than in prior years. This reduces balance-sheet risk and may give IRLAB more flexibility to fund development while it remains pre-commercial.
Losses Have Narrowed SubstantiallyThe improvement in losses suggests cost control and/or a better revenue mix may be developing. Although IRLAB remains unprofitable, continued progress could extend its funding runway and improve the economics of its clinical-stage programs.
Specialized CNS Drug-development FocusA focused CNS strategy gives IRLAB domain specialization in a significant area of unmet medical need. Clinical-stage candidates and a concentrated research platform can support future partnering or milestone opportunities if development succeeds.
Bears Say
Persistent Operating Cash BurnSustained negative operating and free cash flow means the business is not yet self-funding. Continued cash consumption can require additional financing, constrain development priorities, and increase dilution or funding risk before commercial revenue emerges.
Deep Losses And Contracting RevenueSevere losses and a shrinking top line indicate that current revenue is insufficient to cover the cost base. Unless clinical progress translates into partnerships or products, weak operating leverage may persist and continue eroding shareholder capital.
Reliance On External FinancingDependence on equity or other external funding leaves IRLAB exposed to financing availability and potential shareholder dilution. This is a structural risk for a pre-commercial biotech until collaboration income or product sales become dependable.
IRLAB Therapeutics AB Class A News
0GFH FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
Currently, no data Available
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is kr261.87M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is Nov 13, 2026 which is in 75 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
IRLAB Therapeutics AB Class A released its earnings results on Aug 26, 2026. The company reported -kr0.226 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Undervalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 146,382,140 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
IRLAB Therapeutics AB Class A reported an EPS of -kr0.226 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in GB:0GFH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, and Pirepemat, which is undergoing phase IIb clinical trials for the management of postural dysfunction. In the preclinical phase, IRLAB is advancing research programs like IRL942 and 1009, aimed at neurodegenerative conditions and the aging process, as well as IRL757, designed to alleviate apathy in various neurological disorders. Additionally, the company is conducting a research project, P003, focused on creating new therapies for individuals with a recent Parkinson's disease diagnosis. IRLAB Therapeutics AB (publ) was founded in 2013 and has its headquarters in Gothenburg, Sweden.
Alzinova AB
―
AlzeCure Pharma AB
―
BioArctic AB Class B
―
SynAct Pharma AB
―
Saniona AB
―